Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
56.45 USD | -0.05% | +1.07% | +25.64% |
Mar. 08 | Novo Nordisk hopes to launch experimental obesity drug this decade | RE |
Mar. 07 | Transcript : Catalent, Inc. - Special Call |
Evolution of the average Target Price on Catalent, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Catalent, Inc.
UBS | |
Stephens Inc. | |
RBC Capital Markets | |
Deutsche Bank Securities | |
Barclays | |
Wells Fargo Securities | |
Baird | |
Argus | |
Morgan Stanley | |
JPMorgan Chase | |
Jefferies & Co. | |
BofA Securities | |
Nephron Research | |
William Blair & Co. | |
KeyBanc Capital Markets |
EPS Revisions
- Stock
- Equities
- Stock Catalent, Inc. - Nyse
- Consensus Catalent, Inc.